European Commission approves Pfizer's RSV vaccine for adults at increased risk of disease
The expanded EU approval, applicable in all 27 countries of the bloc, is for Pfizer's Abrysvo vaccine, which was backed by the European Medicines Agency's panel of experts in March.
here.
It is a blow for rival drugmaker GSK (GSK.L), opens new tab which has not yet won approval for this population for its RSV vaccine.
RSV is a common virus that can be deadly and is most dangerous for the very young and the elderly.
U.S. drugmaker Pfizer and the UK's GSK are each banking on strong sales of their RSV shots, which they launched in the United States in 2023, as they both face generic competition for their top-selling medicines later this decade.
Both companies hit hurdles in that effort. Sales of both shots were down significantly in the U.S., the biggest market for the pharma industry, during the second autumn vaccination season since the companies launched the shots there.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
19 hours ago
- Daily Mail
Trump demands UK pharmaceutical giants to lower drug costs sparking fears NHS could pay the price if they refuse
Donald Trump has demanded UK pharmaceutical giants lower prices for America and suggested charging others to make up the difference. He said if they didn't, the US would deploy 'every tool in our arsenal' to protect families from 'continued abusive drug prices', sparking fears the NHS will end up paying more. Mr Trump suggested he would use tariffs to push through higher prices if countries resisted. In May Mr Trump signed an executive order demanding drugmakers cut US medicine prices to match those abroad. Yesterday in a letter to 17 pharma companies he said he expected them to deliver on measures by September 29. He asked them to apply 'most favoured nation' pricing to Medicaid, the US health programme for people on low incomes. Mr Trump also asked drugmakers to offer new medicines at the same price in the US as in other developed countries. He said: 'Our citizens pay massively higher prices than other nations pay for the same exact pill... subsidizing socialism aboard [abroad].' British pharma companies AstraZeneca and GSK were among the recipients. Others included Eli Lilly, Johnson & Johnson, Pfizer and Sanofi. The UK Government said it would 'continue to work closely with the US to get the best deal for our pharma industry and deliver mutual benefits for both our countries'.
Telegraph
2 days ago
- Telegraph
Trump threatens NHS with higher drug prices
Donald Trump is pressuring the world's biggest drug makers to raise prices outside of the US in a threat to the NHS. The US president has written to pharmaceutical companies including Britain's GSK and AstraZeneca to demand they lower prices for Americans, suggesting they should pay for it by charging higher fees abroad. It raises the threat of higher costs for the NHS, which is one of the biggest buyers of pharmaceuticals in the world. In the letters sent to the bosses of 17 pharmaceutical companies, Mr Trump demanded that they 'negotiate harder with foreign freeloading nations' and said that 'increased revenues abroad must be repatriated to lower drug prices for American patients and taxpayers'. He also demanded a 'binding commitment' to these goals and declared that 'other nations have been freeloading on US innovation for too long'. Mr Trump made clear that he would use tariffs to push through higher prices if countries resisted. The White House said the president was prepared to use 'trade policy to support manufacturers in raising prices internationally provided that increased revenues abroad are reinvested directly into lowering prices for American patients and taxpayers.' Drug companies have been set a 60-day deadline to 'step up' and meet the president's demands. He has also called for a commitment that companies 'will not offer other developed nations better prices for new drugs than prices offered in the United States.' Trung Huynh, the head of pharma analysis at UBS, said it was clear Mr Trump wanted companies to charge higher prices in the UK and Europe. Alex Schriver of US drug industry body PhRMA said: 'To reduce price differentials with other countries, policymakers should rein in health care middlemen driving up costs for Americans and get foreign countries to pay their fair share for innovative medicines.' Mr Trump has already targeted NHS drug prices as part of his tariff policy. Last month the Telegraph reported that the White House expected the NHS to pay higher prices for American drugs in an attempt to boost the interests of US corporates. Documents released after the US-UK trade agreement was signed earlier this year said the NHS would review drug pricing to take into account the 'concerns of the president'. Thursday's letter was sent to drug companies including Eli Lilly, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer and Sanofi. Share prices slumped after Mr Trump published his letters on his Truth Social account. AstraZeneca and GSK both fell by more than 4pc, while Pfizer was down by more than 2pc. Mr Trump has long expressed rage about the fact that drug companies make between half and 70pc of their profits in the US despite the country accounting for only a fifth of global sales. Drug prices outside of the US can be as little as 30pc of what Americans pay. Profits from the US are used to fund drug research and development that the rest of the world benefits from. Mr Trump has claimed that US citizens effectively pay for foreign healthcare systems through higher drug prices. He said in 2020: 'In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidising socialism aboard [abroad] with skyrocketing prices at home. 'So we would spend tremendous amounts of money in order to provide inexpensive drugs to another country.'
Reuters
2 days ago
- Reuters
French court finds complaint brought by family in Bayer glyphosate case inadmissible, media says
PARIS, July 31 (Reuters) - A French court ruled on Thursday that a complaint brought by a family against Bayer ( opens new tab claiming their son's disabilities were the result of his mother's exposure to glyphosate when pregnant was inadmissible, local media reported. Bayer, which produces the herbicide, said it acknowledged the court's decision, "which did not find the company liable". Lawyers for the Grataloup family said: "It is clearly a big disappointment for the Grataloup family and for us ... The case deserves to be submitted to the appeals court." The lawsuit was one of the first high-profile cases centring specifically on prenatal exposure to glyphosate and congenital malformations in a child. Research has suggested prenatal exposure to glyphosate may affect babies' health at birth, but successful lawsuits have been rare. Bayer has said the product is safe for human use. The German pharmaceutical and biotechnology group has paid around $10 billion to settle disputed claims in the United States that its weedkiller Roundup, based on glyphosate, causes cancer. The European Union last renewed the approval of the use of glyphosate in 2023, through December 2033.
